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INTRODUCTION
BRCA1 and BRCA2 (BRCA1/2) are tumor suppressor genes 
that play a crucial role in the development of hereditary breast 
and ovarian cancer (HBOC) syndrome [1]. Testing for BRCA1/2 
mutations in patients with breast cancer is important because 
knowledge of these mutations helps clinicians to make a 
decision about various options of risk-reduction strategies 
[2,3]. The timing of preventive surgery partly depends on the 
timing of genetic testing and a patient’s age [4]. For example, 
women who know their carrier status before or near the time of 
their breast cancer diagnosis can incorporate this information 
into decisions regarding primary surgical treatment [5]. It is 
necessary for patients with a strong family history of breast 
and ovarian cancer or high risk (>10%) of BRCA1/2 mutations 
to guide them through their choice of preventive surgery, if 
Purpose: We evaluated the clinical role of rapid next-generation sequencing (NGS) for identifying BRCA1/2 mutations 
compared to traditional Sanger sequencing. 
Methods: Twenty-four paired samples from 12 patients were analyzed in this prospective study to compare the 
performance of NGS to the Sanger method. Both NGS and Sanger sequencing were performed in 2 different laboratories 
using blood samples from patients with breast cancer. We then analyzed the accuracy of NGS in terms of variant calling 
and determining concordance rates of BRCA1/2 mutation detection. 
Results: The overall concordance rate of BRCA1/2 mutation identification was 100%. Variants of unknown significance (VUS) 
were reported in two cases of BRCA1 and 3 cases of BRCA2 after Sanger sequencing, whereas NGS reported only 1 case of 
BRCA1 VUS, likely due to differences in reference databases used for mutation identification. The median turnaround time 
of Sanger sequencing was 22 days (range, 14–26 days), while the median time of NGS was only 6 days (range, 3–21 days). 
Conclusion: NGS yielded comparably accurate results to Sanger sequencing and in a much shorter time with respect to 
BRCA1/2 mutation identification. The shorter turnaround time and higher accuracy of NGS may help clinicians make more 
timely and informed decisions regarding surgery or neoadjuvant chemotherapy in patients with breast cancer.
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elected [6].
Traditional Sanger sequencing has a high cost and long 
turnaround time (TAT). In the United States, where commercial 
DNA testing is available, results are often reported within 2 
weeks, but in Western Europe, Sanger sequencing TAT can reach 
4 weeks [3]. However, because of low insurance coverage and 
the labor-intensive and time-consuming work-flow of Sanger 
sequencing analysis for BRCA1/2, a 4- to 6-week TAT is typical 
in South Korea; a 2-week TAT is not generally available in South 
Korea. As a result, most Korean patients newly diagnosed with 
breast cancer have undergone surgery or chemotherapy without 
knowledge of their BRCA1/2 genotype.
Next-generation sequencing (NGS) is a revolutionary high-
throughput nucleotide sequencing method that delivers fast, 
inexpensive, and accurate genomic data  [7]. This method can 
provide similar genetic information for clinicians at a lower cost 
and shorter TAT compared to Sanger sequencing [8]. Therefore, 
it is necessary to elucidate how NGS can be applied and what 
effects on it will have in clinical practice. However, before 
adopting NGS technology for identifying BRCA1/2 mutations, 
validation with traditional Sanger sequencing, the standard 
method of detecting these mutations, should be evaluated. In 
this study, we investigated the performance and diagnostic 
accuracy of NGS compared to Sanger sequencing in detecting 
BRCA1/2 mutations and the role of NGS in clinical practice 
for patients with breast cancer who are candidates for risk-
reduction strategies. 
METHODS
Patients
To evaluate NGS validation as a modality of clinical mutation 
detection compared to Sanger sequencing, blood samples from 
12 patients were used. All patients were prospectively enrolled 
in Severance Hospital between March 2014 and July 2014 
and had been diagnosed with invasive breast cancer (Fig. 1). 
Patients’ clinicopathologic features were summarized in Table 1. 
Written informed consent was obtained before blood sampling. 
Selection criteria for BRCA1/2 screening were based on the 
KOHBRA (Korean Hereditary Breast Cancer) study, which is 
covered by the national insurance system [9]. Both Sanger and 
NGS methods were simultaneously performed in 2 different 
laboratories in Korea. All genetic interpretations of each 
sample were independently performed in both laboratories, 
and sequencing results were not shared between laboratories. 
Sanger sequencing was performed by the clinical laboratory, 
SCL (Seoul, Korea), which is certified by the College of American 
Pathologists laboratory accreditation program. NGS was carried 
out in the clinical genetics laboratory in the Department 
of Laboratory Medicine at Severance Hospital. One of 12 
patients who agreed to participate in the ongoing international 
randomized clinical trial received additional BRACAnalysis 
services (Myriad Genetics Inc., Salt Lake City, UT, USA). Because 
NGS was not fully validated by traditional Sanger sequencing at 
the beginning of the study and was not covered by the Korean 
national insurance system, genetic counseling and clinical 
decision-making for patients regarding their genetic results 
12 Patients enrollment
24 Paired blood samples
12 Next-generation sequencing 12 Sanger sequencing
Fig. 1. Study flowchart.
Table 1. Patients’ clinicopathologic features (n = 12)a)
Characteristic Value
Age (yr) 40.5 ± 7.02
Operation
   BCS 7 (58.3)
   Mastectomy 5 (31.7)
T stage
   T1–2 3 (25.0)
   T3–4 9 (75.0)
Node metastasis
   Node negative 9 (75.0)
   Node positive 3 (25.0)
Estrogen receptor
   Negative 6 (50.0)
   Positive 6 (50.0)
Progesterone receptor
   Negative 4 (33.3)
   Positive 8 (66.7)
HER2
   Negative 12 (100)
   Positive 0 (0)
Ki-67
   Low (<14%) 4 (33.3)
   High (≥14%) 7 (58.3)
   Unknown 1 (8.3)
Adjuvant chemotherapy
   Done 6 (50.0)
   Not done 6 (50.0)
Hormone therapy
   Done 6 (50.0)
   Not done 6 (50.0)
Radiation therapy
   Done 8 (33.3)
   Not done 4 (66.7)
Values are presented as mean ± standard deviation or number (%).
BCS, Breast-conserving surgery; HER2, human epidermal growth 
factor receptor 2.
a)Two patients with bilateral breast cancer were included.
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were accomplished based on traditional Sanger sequencing or 
BRACAnalysis. 
Next-generation sequencing
Genomic DNA was extracted immediately upon arrival 
of the peripheral blood samples at the laboratory using the 
QIAamp DNA Mini Kit (QIAGEN, Victoria, Australia) on a 
QIAcube system (QIAGEN, Hilden, Germany) according to the 
manufacturer’s instructions. The DNA quality was confirmed 
using a Qubit dsDNA HS Assay kit (Life Technologies, Carlsbad, 
CA, USA) on a Qubit2.0 Fluorometer (Life Technologies). If 
the samples were received within 2 days of each other, the 2 
samples were run simultaneously. Library preparation was 
performed using the Ion AmpliSeq BRCA1 and BRCA2 Panel 
primer set, Ion AmpliSeq Library Kit 2.0, and Ion Xpress Barcode 
Adapters (Life Technologies) under the following conditions: 
(1) enzyme activation at 99°C for 2 minutes, (2) denaturation 
at 99°C for 15 seconds, (3) annealing and extension at 60°C 
for 4 minutes (19 cycles), and (4) holding at 10°C. Purification 
was done using the Agencourt AMPure XP reagent (Beckman 
Coulter, Brea, CA, USA) and 70% ethanol on a DynaMagTM-96 
Side Magnet (Life Technologies). Quality control for the 
amplicons was established with the High-Sensitivity DNA kit 
on the Agilent Bioanalyzer (Agilent, Santa Clara, CA, USA). 
Multiplexing was accomplished by combining 100 pmol of 
amplicons into each library tube. Template preparation and 
emulsion polymerase chain reaction (PCR) was performed using 
the Ion Onetouch 200 template Kit v2 on the Ion OneTouch 2 
system with Dynabeads MyOne Streptavidin C1 beads on the 
Ion OneTouch ES (Life Technologies). The spherical particles 
were sequenced on an Ion 314 Chip (Life Technologies) using 
a Ion PGM Sequencing 200 Kit v2 on the Ion PGM system (Life 
Technologies). 
Ion Torrent reads were initially analyzed for variant detection 
using the Ion Torrent Variant Caller, which is available at the 
Life Technology Torrent Browser Plugin Store. Visual con-
firmation of the identified variants was accomplished with 
Integrated Genomics Viewer software from Broad Institute 
(Cambridge, MA, USA; http://www.broadinstitute.org/igv/). 
Further data review of missense variants was performed by 
using online software for predicting alterations of protein 
function, such as SIFT (Sorting Intolerant From Tolerant; http://
sift.bii.a-star.edu.sg/index.html) and PolyPhen-2 (http://genetics.
bwh.harvard.edu/pph2/index.shtml). Filtering of the data was 
done manually by reviewing all variants identified by the Ion 
Torrent Variant Caller.
Sanger sequencing 
Genomic DNA was isolated using the QIAamp DNA Mini 
Kit. Sanger sequencing was performed as follows. Briefly, PCR 
amplification was performed using F-Taq polymerase (Solgent, 
Korea). Each 25-μL reaction contained 1X PCR buffer, 1.5-
mmol/L MgCl2, 2 mmol/L of each dNTP, 5 pmol/L each of the 
forward and reverse primers, 0.5 U F-Taq polymerase, and 100-
ng genomic DNA. The thermal cycling program included the 
follow steps: (1) 94°C for 5 minutes, (2) 94°C for 30 seconds, 
(3) appropriate annealing temperature for 30 seconds, (4) 72°C 
for 45 seconds, and (5) 72°C for 3 minutes. Steps 2–4 were 
repeated for 30 cycles. Primers were synthesized according to 
published primer sequences when available or were custom-
designed [10]. Full coding regions of the BRCA1 and BRCA2 
genes were amplified using single-locus conventional PCR. The 
targeted region was defined as the complete coding regions 
of BRCA1 and BRCA2 and approximately 20 bp of noncoding 
DNA flanking the 5’ and 3’ ends of each exon. Each PCR 
amplicon was treated with 20-μL reaction mixture comprising 
3 U exonuclease I, 5X exonuclease I buffer, and 1.7 U FastAP 
thermosensitive alkaline phosphatase (Fermentas, Waltham, 
Massachusetts, USA) and incubated at 37°C for 45 minutes, 
followed by heat-inactivation at 80°C for 10 minutes. Cycle 
sequencing was performed using the BigDye Terminator kit 
v1.1 (Applied Biosystems, Foster City, CA, USA) according to 
the manufacturer’s instructions. Sequencing products were 
analyzed on a 3130xl Genetic Analyzer (Applied Biosystems). 
The SeqScape software v2.7 (Applied Biosystems) was used for 
visualization and sequence alignment of Sanger data.
Interpretation of genomic data
References used for mutation identification by Sanger 
sequencing were Breast Cancer Information Core database (BIC; 
http://research.nhgri.nih.gov/bic/) and the Human Genome 
Mutation Database (HGMD; http://www.hgmd.org). Reporting 
of Sanger sequencing was performed using guidelines for 
mutation nomenclature of the Human Genome Variation 
Society (http://www.hgvs.org). References used for NGS 
analysis were based on the BIC, HGMD, and Database of Single 
Nucleotide Polymorphisms (dbSNP; http://www.ncbi.nim.nih.
gov/SNP/). Significant mutations were considered “positive” for 
BRCA1/2 mutations, and variants of unknown significance (VUS) 
and nonsignificant variants were considered “negative.” 
Statistical analysis
Comparison of the continuous variable (TAT) was performed 
using the Student t-test. Numbers of mutation and VUS were 
compared using the chi-square test. All tests were 2-sided, 
and P-values less than 0.05 indicated statistical significance. 
Statistical analysis was performed using IBM SPSS Statistics ver. 
20.0 (IBM Co., Armonk, NY, USA).
Ethics
The authors confirm that all ongoing and related trials 
for this intervention are registered. All patients agreed with 
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enrollment of the study. They signed informed consent forms 
before enrollment. This study was approved by the Severance 
Hospital Institutional Review Board (2013-1411-001), and the 
ClinicalTrials.gov identifier for this study is NCT02151747. 
RESULTS
The median age of patients in our study was 36 years (range, 
32–53 years), and 7 patients were less than 40 years old. Ten 
patients had primary breast cancer, 2 patients had metastatic 
breast cancer, and bilateral breast cancer was mani fested in 2 
patients. Three patients had a second-degree family history of 
breast or ovarian cancer. 
BRCA1/2 mutations were identified in 2 patients (2 of 12, 
16.6%). Both Sanger sequencing and NGS identified one BRCA1 
and one BRCA2 mutation carrier; thus, the overall accuracy 
rate of NGS was 100% (specificity 100% and sensitivity 100%). 
An example of the pedigree charts for a patient with BRCA1 
mutation was illustrated in Fig. 2. However, among 10 patients 
whose Sanger and NGS analyses yielded negative BRCA1/2 
mutation results, 1 patient received additional BRACAnalysis 
that included large genomic rearrangement test. This additional 
analysis revealed a deleterious mutation that was not detected 
by either Sanger sequencing or NGS.
Sanger sequencing identified 2 patients with BRCA1 VUS 
and 3 patients with BRCA2 VUS, although NGS reported only 
1 patient with BRCA1 VUS. The reported VUS from Sanger 
se quencing were c.5590G>A, c.4883T>C, c.10234A>G, 
c.10234A>G, c.671-8A>G, and c.811G>A. The reported VUS 
from NGS were c.671-8A>G and c.811G>A in a patient less than 
40 years old with metastatic breast cancer, which were also 
de tected in this patient by Sanger sequencing. Differences in 
BRCA1/2 variants identification between the two sequencing 
me thods were not statistically different (BRCA1, P=1.00; BRCA2, 
P=0.21) (Table 2).
Nonsignificant variants, including some synonymous and 
missense variants, were detected with NGS more often than 
with Sanger sequencing. The nonsignificant variants detected 
only by NGS were c.2510A>G (zygosity=19%), c.1961delA 
(zygosity=19%), c.68-4A>T (zygosity=17%), c1804G>A 
(zygosity=23%), c.3860delA, c8926delA (zygosity=32%), 
c.8941G>A (zygosity=22%), c.8942A>G (zygosity=14%), 
c.4563A>G, c.6513G>C, and c.7397T>C. Three variants 
identified by NGS (c.4563A>G, c.6513G>C, and c.7397T>C 
were found in all 12 patients as homozygous synonymous or 
missense variants of BRCA2. However, these three variants 
were not detected as variants of BRCA2 as reported by Sanger 
sequencing. Variants called with an inadequate zygosity 
possibility (zygosity<40–60%) using NGS disappeared after 
retesting. The only nonsignificant variant exclusively identified 
by Sanger sequencing was c.1114C>A. 
The median TAT of Sanger sequencing was 22 days (range, 14–
26 days), while the median TAT of NGS was only 6 days (range, 
3–21 days) (Fig. 3). The median difference between Sanger 
Lung ca Breast ca
Stomach ca
Breast ca Breast ca (48)
BRCA1 c.3700-3704delGTAAA
P
Fig. 2. An example of the pedi-
gree charts for a patient with 
BRCA1 mutation. ca, cancer.
Table 2. Turnaround time (TAT) and genotype comparison 
between next-generation and Sanger sequencing
TAT & genotype Sanger NGS P-value
TAT (day) 22 (14–26) 6.5 (3–21) <0.001
BRCA1 1.00
   No mutation 9 10
   Mutation 1 1
   VUS 2 1
BRCA2 0.21
   No mutation 8 11
   Mutation 1 1
   VUS 3 0
Values are presented as median (range) or number.
VUS, variant of unknown significance.
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sequencing and NGS TAT was statistically significant (P < 
0.001) at 11 days (range, 1–21 days).
DISCUSSION
Our current study demonstrated the accuracy and short TAT 
of NGS compared to Sanger sequencing in detecting BRCA1/2 
mutations in breast cancer patients. The overall accuracy rate 
of detecting BRCA1/2 mutations with NGS was 100% with a 
faster TAT compared to Sanger sequencing. However, some 
VUS identified by Sanger sequencing were not identically 
reported by NGS; specifically, many nonsignificant variants 
that were considered to be no mutation were identified by NGS 
but not by Sanger sequencing. This discrepancy was likely due 
to differences in references used for variant nomenclature. 
Because of the lack of a universally accepted variant reference, 
a more sophisticated classification of variant nomenclature 
using existing references is necessary to avoid variant misin-
ter pretation and miscommunication between laboratory inves-
tigators and physicians, especially during early phase testing of 
NGS BRCA1/2 mutation identification.
In this study, some variants with a nonsignificant zygosity 
possibility not detected by Sanger sequencing were reported 
in two early NGS cases. To reduce interference, we retested the 
first 2 NGS samples from these patients, and the nonsignificant 
zygosity possibility subsequently disappeared. These errors 
occurred, even though we used a commercially-available 
BRCA1/2 panel of Ion Torrent sequences, indicating a learning 
curve exists for achieving the full accuracy of NGS testing. 
The sequencing platform, analytical software, and filter 
settings used can significantly influence the specificity and 
sensitivity of NGS  [8,11]. Thus, it is important to set appro-
priate filtering preferences to facilitate more rapid esta bli-
shment of NGS BRCA1/2 mutation testing. Feliubadaló et 
al. [11] demonstrated the optimal algorithm with various 
filter applications of filters in NGS BRCA1/2 testing, and they 
observed the overall sensitivity and specificity of NGS can 
differ according to selected filter settings. We have summarized 
previous studies that evaluated the accuracy of NGS in 
identifying BRCA1/2 mutations in Table 3 [8,11-15]. In general, 
both sequencing platform and filter settings affected sensitivity 
and specificity, which, in these studies, ranged from 95% to 
100% and 80% to 100%, respectively. In our study, we observed 
no false-negative or -positive cases when detecting BRCA1/2 
mutations by NGS compared to Sanger sequencing, which is 
consistent with previous study [8,11-15]. Therefore, NGS is an 
alternative diagnostic tool to Sanger sequencing in detecting 
BRCA1/2 mutations.
Knowing an individual’s BRCA1/2 status can critically in-
fluence her selection of surgical method related to breast cancer 
prevention or treatment [5]. Current National Comprehensive 
Cancer Network guidelines caution women with a known or 
suspected genetic predisposition to breast cancer against breast-
conserving surgery [16]. Alternately, contralateral prophylactic 
mastectomy with ipsilateral mastectomy can be a surgical risk-
reduction strategy at the time of definitive surgery, and the 
rate of performed contralateral prophylactic mastectomy has 
been increasing in the United States [17]. Therefore, knowing 
one’s genetic susceptibility to breast cancer before surgery 
and providing corresponding treatment options, such as risk-
reduction surgery, in patients with breast cancer or suspicious 
HBOC syndrome should be achieved as soon as possible. 
However, it is difficult to obtain this genetic information before 
surgery in Korea where rapid commercial sequencing services 
are unavailable. Traditional Sanger sequencing requires a TAT 
of 4–6 weeks in Korea, and the cost of Sanger sequencing for 
BRCA1/2 is often between US $1,100–$2,800. Recently, the 
United States Supreme Court invalidated Myriad Genetics’ 
patent of the BRCA1/2 genes of Myriad in 2013 [18], after which 
several clinical laboratories in the United States began to 
offer NGS testing for BRCA1/2 mutations at lower prices than 
previously available [19-21]. This new availability will generate 
much controversy surrounding BRCA1/2 testing [20,21], as the 
cost for this testing has decreased in other countries other than 
the United States. In addition, the application of shorter TAT 
NGS BRCA1/2 testing in high-risk patients with breast cancer 
compared to Sanger sequencing will change the pattern of 
clinical practice with respect to surgical option decision-making.
Although we have demonstrated NGS testing is viable in 
clinical practice, several issues remained to be resolved. Anno-
ta tion of VUS differs between NGS and Sanger sequencing due 
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to reference database differences if independent laboratories 
per formed the sequencing. This discrepancy makes it difficult 
for clinicians to provide comprehensive information about 
VUS for their patients. While increasingly sophisticated me-
thods to address the functional significance of individual 
VUS are developing [22,23], many BRCA1/2 variants remain 
unclassified [23], and they could be classified differently based 
which references are used. For example, a previous study 
reported a reclassification rate of 77% over an 8-year period 
[24]. Furthermore, the BIC database ceased to be updated by 
Myriad Genetics after the company stopped contributing 
their BRCA1/2 results in 2004 [19,21]. Therefore, it is not yet 
possible to report VUS using a universally accepted reference. 
Using multiple references from international networks to 
collect and interpret VUS data including clinical, functional, 
pathological, and in silico analyses may provide a way to share 
comprehensive BRCA1/2 information [25]. For now, using a 
single reference for interpreting VUS data should be avoided. 
Debates regarding the interpretation of VUS are ongoing, and 
further investigations are needed to establish a universally 
accepted VUS interpretation method. 
National medical systems approving NGS as a screening 
tool for BRCA1/2 mutation are different among countries. For 
example, NGS testing for BRCA1/2 mutations is not covered by 
the Korean national insurance system and is not considered a 
standard diagnostic tool. Only Sanger sequencing for BRCA1/2 
mutations in patients with breast cancer is covered by the 
national insurance due to a lack of robust validation for 
BRCA1/2 mutation testing by NGS, although several clinical 
laboratories in the United States and other Western countries 
have begun to provide comprehensive BRCA1/2 testing using 
NGS. However, faster TAT, lower cost, and the technical 
achievement of managing and exploring NGS data may over-
come this hurdle for many countries. Some researchers have 
highlighted that genomic testing by NGS is very cost-effective 
and will eventually revolutionize clinical care [26], and a 
genotype-first approach using NGS is one strategy for managing 
complex diseases [27]. For these reasons, developing panels for 
evaluating cancer genes, including BRCA1/2, which are high-
penetrance genes and most common in patients and families 
with HBOC syndrome are critical for positive patient outcomes 
[28,29]. These perspectives suggest that NGS testing for BRCA1/2 
and other genes associated with HBOC syndrome will hold a 
central place in applying novel testing of breast cancer genetics. 
Identifying large genomic rearrangements of BRCA1/2 is 
essen tial for providing more accurate genomic information 
to patients. Although commercial BRCA testing detected 
these rearrangements, neither NGS nor Sanger sequencing 
de tected them in our study. Because conventional Sanger 
se quencing is not suitable for identifying large genomic re-
arrange ments, additional testing, such as multiplex ligation-
dependent probe amplification (MLPA), is necessary in some 
patients with initially negative BRCA1/2 results as provided 
by Sanger sequencing [30]. Feliubadaló et al. [11] utilized NGS 
for identifying large genomic rearrangements, but external 
validation of this method is still underway in Korea. However, 
if NGS can detect large genomic rearrangements in BRCA genes 
without additional methods like MLPA, NGS would be more 
cost-effective and possibly more accurate than conventional 
Sanger sequencing.
The shortcoming of this study is its small number of enrolled 
patients despite its prospective design. A further extension 
of patient enrollment to ensure data validation is needed. 
However, this study demonstrates the clear advantage of 
testing BRCA1/2 using NGS compared to conventional Sanger 
sequencing. Shorter TAT and high accuracy of NGS may enable 
clinicians and patients make more timely and informed 
decisions regarding surgery and neoadjuvant chemotherapy 
options for preventing or treating breast cancer.
In conclusion, NGS yielded comparably accurate results to 
Sanger sequencing and in a much shorter time with respect 
to BRCA1/2 mutation identification. The shorter TAT and 
higher accuracy of NGS may help clinicians make more timely 
and informed decisions regarding surgery or neoadjuvant 
chemotherapy in patients with breast cancer.
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